- Home
- GF vs ALLK Comparison
GF vs ALLK Comparison
Compare GF & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- ALLK
- Stock Information
- Founded
- GF 1990
- ALLK 2012
- Country
- GF Germany
- ALLK United States
- Employees
- GF N/A
- ALLK N/A
- Industry
- GF Investment Managers
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- ALLK Health Care
- Exchange
- GF Nasdaq
- ALLK Nasdaq
- Market Cap
- GF 136.3M
- ALLK 127.5M
- IPO Year
- GF N/A
- ALLK 2018
- Fundamental
- Price
- GF $8.44
- ALLK $0.58
- Analyst Decision
- GF
- ALLK Hold
- Analyst Count
- GF 0
- ALLK 5
- Target Price
- GF N/A
- ALLK $1.67
- AVG Volume (30 Days)
- GF 28.1K
- ALLK 333.9K
- Earning Date
- GF 01-01-0001
- ALLK 11-11-2024
- Dividend Yield
- GF 0.82%
- ALLK N/A
- EPS Growth
- GF N/A
- ALLK N/A
- EPS
- GF N/A
- ALLK N/A
- Revenue
- GF N/A
- ALLK N/A
- Revenue This Year
- GF N/A
- ALLK N/A
- Revenue Next Year
- GF N/A
- ALLK N/A
- P/E Ratio
- GF N/A
- ALLK N/A
- Revenue Growth
- GF N/A
- ALLK N/A
- 52 Week Low
- GF $7.38
- ALLK $0.56
- 52 Week High
- GF $9.41
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- GF 48.17
- ALLK 39.39
- Support Level
- GF $8.31
- ALLK $0.58
- Resistance Level
- GF $8.38
- ALLK $0.63
- Average True Range (ATR)
- GF 0.06
- ALLK 0.06
- MACD
- GF -0.02
- ALLK -0.00
- Stochastic Oscillator
- GF 24.14
- ALLK 20.83
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a United States-based non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.